Wire · opportunities
An FDA Committee Just Voted in Favor of Peptides—Despite the Agency's Opposition
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 July 2026 · Fusion42 review
An FDA advisory committee voted to recommend two peptides (BP-157 and KPV) for inclusion on the 503A bulks list, allowing compounding pharmacies to dispense them, overruling FDA staff opposition and bypassing the standard drug approval process. The decision follows a 2023 FDA ban on these substances and reflects pressure from telehealth companies and patient advocates citing grey-market alternatives as a safety concern.
This Wire brief sits within Fusion42's coverage of Digital Health, and 12 sources have reported it between 22 Jul 2026 and 31 Jul 2026.
◆ ◆ The Wire takeaway
If you're building telehealth or a peptide supply business, the FDA just handed you a regulatory pathway that skips years of drug approval—but the committee vote is non-binding and a public rulemaking battle is coming. The grey market is now your competitive benchmark; if you can't beat China's price and speed through legal compounding, customers will choose the bodega.
◆ Coverage
12 sources · first reported 22 Jul 2026 · latest 31 Jul 2026
◆ Related on Wire
◆ Topics